Johnson & Johnson Company History Timeline

1886
Where it all began In 1886, three brothers Robert Wood Johnson, James Wood Johnson and Edward Mead Johnson began the company, Johnson Johnson, in New Brunswick, New Jersey in the United States.
1886 Johnson brothers begin producing dressings in New Brunswick, New Jersey.
1887
Robert Wood Johnson served as the first president the company became incorporated in 1887 and throughout the nineteenth century, Robert worked to improve sanitation practices.
1891
The establishment of a bacteriological laboratory in 1891 gave research a boost, and by the following year the company had met accepted requirements for a sterile product.
1893
1893 Johnson's Baby Powder is introduced.
1894
In 1894, J J s heritage baby business began, by the launch of maternity kits.
1895
In 1895, he started a side business called The American Ferment Company.
1905
In 1905, he formerly incorporated as Mead Johnson Company the specialty product being digestive aid.
1910
A few years later, in 1910, Mead Johnson Company developed a blockbuster infant formula that had the distinction of being the first physician-recommended breast milk replacement in the United States.
1915
Ethicon, Inc. edit In 1915, George F. Merson opened a facility in Edinburgh for the manufacturing, packaging and sterilizing of catgut, silk and nylon sutures.
1919
1919 International expansion begins with the establishment of Johnson Johnson Canada.
1924
1924 Overseas expansion begins with the establishment of Johnson Johnson Limited in the United Kingdom.
1934
On 23 October 1934, he founded the N.V. Produkten Richter in Turnhout.
1943
In 1943 Johnson wrote a credo outlining the company's four areas of social responsibility first to its customers second to its employees third to the community and environment and fourth to the stockholders.
1944
That year, J J also continued its record of issuing dividends to shareholders every quarter since 1944, increa sed its dividend for the 43rd straight year, and achieved a double-di git increase in earnings for the 19th consecutive year.
In 1944, he decided an IPO would be the best way to raise capital for expansion, accelerating the rate at which his empire was spreading across the world.
1947
Merson's company in 1947, and this was renamed Ethicon Suture Laboratories.
1949
One of J J s subsidiaries is Ethicon, which is a manufacturer of surgical sutures and wound closure devices. It was incorporated as a separate company in 1949 so as to expand and diversify the J J product line.
1956
In 1956, Paul Janssen founded his own research laboratory within the Richter-Eurpharma company of his father.
1959
In 1959, Johnson Johnson acquired McNeil Laboratories and a year later, the company was able to sell Tylenol for the first time without a prescription.
1960
1960 McNeil Labs introduces Tylenol as an over-the-counter OTC pain reliever.
1961
On 24 October 1961, the company was acquired by the American corporation Johnson Johnson.
To bolster its drug R D efforts, J J completed its first major pharmaceutical deal since the 1961 purchase of Janssen Pharmaceutica.
The joining of Janssen. It was in 1961 that Belgium s Janssen Pharmaceutica N.V. joined the J J Family of Companies.
1963
Also, 1963 marks the last year that JOHNSON'S Baby Powder is sold in tins.
1967
The deal, announced in August of 1967, involved an all-stock purchase both common and preferred worth 240 million.
1968
Under the General's leadership, annual sales grew from 11 million to 700 million at the time of his death in 1968.
1973
Sellars, Hofmann's prot g , had become chairman in 1973 , and served in that position for three years.
1975
1975 Through a significant price decrease, Tylenol is transformed into a mass-marketed product.
1981
In 1981 the company extended its involvement in eye care through the acquisition of Frontier Contact Lenses.
1982
Following the Credo is what saved the firm s reputation during the Chicago Tylenol murders of 1982.
1986
In 1986 J J acquired LifeScan, Inc., maker of at-home blood-monitoring products for diabetics.
1988
Following the acquisition of Frontier Contact Lenses, which was renam ed Vistakon, J J introduced the Acuvue brand of disposable contac t lenses in the United States in 1988.
1989
Net earnings had nearly quad rupled since 1989, while net sales nearly tripled over the same perio d.
Burke and Clare retired in 1989 and were succeeded by three executives CEO and Chairman Ralph S. Larsen, who came from the consumer sector Vice-Chairman Robert E. Campbell, who had headed the professional sector and President Robert N. Wilson, who had headed the pharmaceutical sector.
1992
Another subsidiary that grew through acquisitions in this period was Ethicon Endo-Surgery, Inc., which had been spun off from Ethicon in 1992 to concentrate on endoscopic, or minimally invasive, surgical instruments.
1994
Risperdal is well-known due to the controversy in the US following its product launch in 1994.
In 1994, the first coronary stent was created by J J and was called the Palmaz-Schatz stent.
1994 Neutrogena Corporation is acquired.
1995
J J spent another billion dolla rs in 1995 for the clinical diagnostics unit of Eastman Kodak Company , which was particularly strong in the areas of clinical chemistry, w hich involves the analysis of simple compounds in the body, and immun o-diagnostics.
1996
Another large acquisition occurred in 1996 when J J spent about 1.8 billion for Cordis Corporation, a world leader in the treatment of cardiovascular diseases through its stents, balloons, and catheters.
1998
In late 1998 J J announced that it would reduce its workforce by 4,100 and close 36 plants around the world over the succeeding 18 months.
1998 DePuy edit DePuy was acquired by J J in 1998, rolling it into the Johnson Johnson Medical Devices group.
1999
Also in 1999 J J acquired the dermatological skin care business of S.C. Johnson Son, Inc.--which was primarily made up of the Aveeno brand--for an undisclosed amount.
Propulsid had nearly 1 billion in sales in 1999.
2000
In the meantime, Johnson Johnson expanded its OTC pain reliever lineup in 2000 by acquiring the St Joseph brand, best known for its orange-flavored, low-dose aspirin, which was in wide use as a doctor -recommended daily therapy.
The year 2000 got off to a rough start for the company, however, as it was forced to withdraw from the market a prescription heartburn medication, Propulsid, after the drug had been linked to 100 deaths and hundreds of cases of cardiac irregularity.
2001
2001 ALZA Corporation is purchased for 13.4 billion.
In 2001, McNeil Consumer Healthcare changed its name to McNeil Consumer Specialty Medicals Products.
2002
William C. Weldon became the Chairman and CEO of J J in 2002.
2003
In pharmaceuticals, J J once again turned acquisiti ve to bolster a somewhat somnolent drug-development pipeline, buying Scios Inc. in April 2003.
Beginning in 2003, J J became involved in a series of litigations with Boston Scientific involving patents covering heart stent medical devices.
Finally, the company introduced Splenda, a no-calorie sweetener that by 2003 would garner the top position in United States retail sales of tabletop sweeteners.
2004
On 27 October 2004, the Paul Janssen Research Center was founded.
Sales of Natrecor rose to 384 million by 2004, bu t the potential blockbuster status of the drug came into question fol lowing reports that it was damaging patients' kidneys.
During 2004 revenues reached 47.35 billion and increased for the 71st consecutive year.
2006
In 2006, J J acquired Pfizer Consumer Healthcare for 16.6 billion in cash.
2008
In 2008 J J announced it would acquire Mentor Corporation for 1 billion and merge its operations into Ethicon.
2010
In June 2010, Centocor Ortho Biotech acquired RespiVert, a privately held drug discovery company focused on developing small-molecule, inhaled therapies for the treatment of pulmonary diseases.
2011
In June 2011, Centocor Ortho Biotech changed its name to Janssen Biotech, Inc. as part of a global effort to unite the Janssen Pharmaceutical Companies around the world under a common identity.
2012
In May 2012 Johnson Johnson China Investment Ltd announced it would acquire surgery blood clotting developer, Guangzhou Bioseal Biotechnology Co., Ltd.
In 2012, J J agreed to pay US 181 million to 26 states in order to settle these claims.
Alex Gorsky was appointed Chief Executive Officer of Johnson Johnson in 2012.
J J s pharmaceuticals segment was the fastest growing pharma business in the US, Europe and Japan in 2012.
2013
In August 2013, the company acquired Aragon Pharmaceuticals, Inc.
2014
In November 2014, the company acquired Alios BioPharma, Inc. for 1.75 billion.
In December 2014, the company announced it would co-develop MacroGenics cancer drug candidate MGD011 which targets both CD19 and CD3 proteins in treating B-cell malignant tumours.
2015
In January 2015, the company announced it will utilise Isis Pharmaceuticals' RNA-targeting technology to discover and develop antisense drugs targeting autoimmune disorders of the gastrointestinal tract, with the partnership potentially generating up to 835 million for Isis.
In November 2015, Biosense Webster, Inc. acquired Coherex, Medical Inc. expanding the companies range of treatment options for patients with atrial fibrillation.
2016
In March 2016, J Js Ethicon business unit announced it would acquire NeuWave Medical, Inc.
2017
In July 2017, Johnson Johnson Vision Care, Inc announced that its Abbott Medical Optics subsidiary would acquire TearScience, who recently received FDA approval for an office-based approach to imaging meibomian glands and treating meibomian gland dysfunction.
Feely, J., Fisk, M. Hopkins, J. 2017, September 22 . Johnson Johnson alerted to risk of asbestos in talc in '70s, files show.
According to IMS Health, the total global pharma market is expected to grow approximately 4.5 annually and reach a market size of around US 1.2 trillion by 2017.
Daniel King joined Asbestos.com in 2017.
2018
In May 2018, Janssen announced it would acquire BeneVir Biopharm, Inc. for an undisclosed sum.
Girion, L. 2018, December 14 . Johnson Johnson knew for decades that asbestos lurked in its baby powder.
2019
In December 2019 XBiotech Inc. announced it would sell its novel antibody treatment bermekimab that neutralizes interleukin-1 alpha IL-1 to Janssen Biotech, Inc. for 750 million plus up to a further 600 million.
In 2019, Johnson Johnson announced the release of photochromic contact lenses.
2020
February 10, 2020 In honor of Presidents' Day, the company's chief historian shares some stories of special company connections to former United States presidents, including the day one leader awarded Johnson Johnson with a medal for a century's worth of innovation.
Founded
1886
Company Founded
Headquarters
New Brunswick, NJ
Company Headquarter
Founders
James Johnson,Robert Johnson I,Edward Johnson
Company Founders

Similar Companies

Company NameascdescFounded DateascdescRevenueascdescEmployee Sizeascdesc
Amgen1980
Amgen
1980
1980
$23.8B
$23.8B
19,200
19,200
Biogen1978
Biogen
1978
1978
$12.3B
$12.3B
7,300
7,300
Becton Dickinson1897
Becton Dickinson
1897
1897
$16.0B
$16.0B
76,032
76,032
Gilead Sciences1987
Gilead Sciences
1987
1987
$22.1B
$22.1B
11,000
11,000
Celgene1986
Celgene
1986
1986
$12.2B
$12.2B
7,467
7,467
Stryker1941
Stryker
1941
1941
$12.4B
$12.4B
19,232
19,232
Pfizer1849
Pfizer
1849
1849
$53.6B
$53.6B
92,400
92,400
Merck & Co.1891
Merck & Co.
1891
1891
$14.8B
$14.8B
69,000
69,000
Thermo Fisher Scientific2006
Thermo Fisher Scientific
2006
2006
$20.9B
$20.9B
70,000
70,000
St. Jude Medical Center1957
St. Jude Medical Center
1957
1957
2,600
2,600
Find Jobs from Similar Companies
Personalize your job search. Where would you like to work?
0 selections